title: Recent trials in critical care nephrology.
abstract: Several large observational studies or randomized controlled trials in the field of critical care nephrology have been completed and reported, or recently completed or have recently begun recruitment. These studies provide important information to guide our appreciation of current practice and consider new potentially effective intervention for the prevention or attenuation of acute kidney injury or suggest new avenues for the use of renal replacement therapy (RRT) in the treatment of sepsis. In particular, two studies, the ATN study and the RENAL study (both multicenter randomized controlled trials of > 1,000 patients) provide, for the first time, level I evidence to guide the practice of RRT in critically ill patients and to better define the optimal intensity of such RRT in this setting. Clinicians practicing in the field of critical care nephrology need to be aware of these trials, their details, their findings or design or current recruitment rate and likely time of completion to continue to offer their patients the highest level of evidence-based medical care.
authors.forename: Rinaldo
authors.initials: R
authors.lastname: Bellomo
authors.forename: Paul M
authors.initials: PM
authors.lastname: Palevsky
authors.forename: Sean M
authors.initials: SM
authors.lastname: Bagshaw
authors.forename: Noel
authors.initials: N
authors.lastname: Gibney
authors.forename: Finlay A
authors.initials: FA
authors.lastname: McAlister
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Honore
authors.forename: Olivier
authors.initials: O
authors.lastname: Joannes-Boyau
authors.forename: John
authors.initials: J
authors.lastname: Prowle
authors.forename: Michael
authors.initials: M
authors.lastname: Haase
authors.forename: Dinna N
authors.initials: DN
authors.lastname: Cruz
authors.forename: Claudio
authors.initials: C
authors.lastname: Ronco
mesh_terms: D058186:Acute Kidney Injury / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D000069059:Atorvastatin; D003422:Critical Care / Q000379:methods*; D016638:Critical Illness; D020000:Decision Support Systems, Clinical; D019317:Evidence-Based Medicine / Q000592:standards; D005260:Female; D006440:Hemofiltration; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007902:Length of Stay; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011758:Pyrroles / Q000627:therapeutic use; D011897:Random Allocation; D016032:Randomized Controlled Trials as Topic; D012079:Renal Circulation / Q000502:physiology; D006435:Renal Dialysis / Q000379:methods*; D017582:Renal Replacement Therapy / Q000379:methods*; D018805:Sepsis / Q000150:complications / Q000453:epidemiology; D012720:Severity of Illness Index; D015996:Survival Rate
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin